Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Massanella, Marta ^a,b   Ouchi, Dan ^a   Marfil, Silvia ^a   Llibre, Josep M ^c   Puertas, Maria C ^a   Buzón, María J ^a   Richman, Douglas D ^b   Orna, Elisa ^c   Stevenson, Mario ^d   Gatell, Josep M ^e   Domingo, Pere ^f   Negredo, Eugènia ^c,g   Martinez Picado, Javier ^a,g,h   Clotet, Bonaventura ^a,c,g   Blanco, Julià ^a,g  

^a FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d UNIVERSITY OF MIAMI   (United States)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

^h INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD14 ANTIGEN; D DIMER; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RALTEGRAVIR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER; INTEGRASE INHIBITOR;

ADULT; ARTICLE; BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; FEMALE; GROUPS BY AGE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS REPLICATION; BLOOD; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; BIOMARKERS; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RALTEGRAVIR POTASSIUM;

EID: 84914694259     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114142     Document Type: Article

References (43)

1. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
2. Harris LD, Tabb B, Sodora DL, Paiardini M, Klatt NR, et al. (2010) Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques. J Virol 84: 7886-7891.
3. Rotger M, Dalmau J, Rauch A, McLaren P, Bosinger S, et al. (2011) Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest 121: 2391-2400.
4. Catalfamo M, Di Mascio M, Hu Z, Srinivasula S, Thaker V, et al. (2008) HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A 105: 19851-19856.
5. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee T-H, et al. (2011) A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response. J Infect Dis 203: 960-968.
6. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, et al. (2013) Dysbiosis of the gut microbiota is associated with hiv disease progression and tryptophan catabolism. Sci Transl Med 5: 193ra91.
7. Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, et al. (2011) Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 204: 1217-1226.
8. Appay V, van Lier RAW, Sallusto F, Roederer M (2008) Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 73: 975-983.
9. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5: e203.
10. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283-2296.
11. Cassol E, Misra V, Holman A, Kamat A, Morgello S, et al. (2013) Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infectious Diseases 13: 203.
12. Massanella M, Negredo E, Clotet B, Blanco J (2013) Immunodiscordant responses to HAART - mechanisms and consequences. Expert Rev Clin Immunol 9: 1135-1149.
13. Massanella M, Negredo E, Pérez-Alvarez N, Puig J, Ruiz-Hernández R, et al. (2010) CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS 24: 959-968.
14. Negredo E, Massanella M, Puig J, Pérez-Alvarez N, Gallego-Escuredo JM, et al. (2010) Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis 50: 1300-1308.
15. Massanella M, Curriu M, Carrillo J, Gómez E, Puig J, et al. (2013) Assessing main death pathways in T lymphocytes from HIV infected individuals. Cytometry A 83: 648-658.
16. Sandler NG, Wand H, Roque A, Law M, Nason MC, et al. (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203: 780-790.
17. Deeks SG (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62: 141-155.
18. Madden E, Lee G, Kotler DP, Wanke C, Lewis CE, et al. (2008) Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS 22: 707-715.
19. Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, et al. (2011) Higher levels of CRP, Ddimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 203: 1637-1646.
20. Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, et al. (2013) Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. AIDS 27: 1735-1742.
21. Gazzola L, Tincati C, Bellistrì GM, Monforte A, Marchetti G (2009) The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 48: 328-337.
22. Massanella M, Martinez-Picado J, Blanco J (2013) Attacking the HIV Reservoir from the Immune and Viral Perspective. Curr HIV/AIDS Rep 10: 33-41.
23. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, et al. (2012) Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12: 607-614.
24. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, et al. (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16: 460-465.
25. Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, et al. (2013) Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 208: 1436-1442.
26. Llibre JM, Buzón MJ, Massanella M, Esteve A, Dahl V, et al. (2012) Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther 17: 355-364.
27. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, et al. (2010) The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 7: e1000321.
28. Byakwaga H, Kelly M, Purcell DFJ, French MA, Amin J, et al. (2011) Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis 204: 1532-1540.
29. Massanella M, Esteve A, Buzón MJ, Llibre JM, Puertas MC, et al. (2013) Dynamics of CD8 T-Cell Activation after Discontinuation of HIV Treatment Intensification. J Acquir Immune Defic Syndr 63: 152-160.
30. Massanella M, Negredo E, Puig J, Puertas MC, Buzón MJ, et al. (2012) Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV infected HAART-supressed individuals with poor CD4 T-cell recovery. AIDS 26: 2285-2293.
31. Negredo E, Massanella M, Puertas MC, Buzón MJ, Puig J, et al. (2013) Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. J Antimicrob Chemother 68: 2358-2362.
32. bates D, Maechler M, Bolker B (2012) lme4: Linear mixed-effects models using S4 classes. R package version 0.999999-0. Available: http://CRAN.R-project.org/package5lme4 and http://CRAN.R-project.org/package5lme4.
33. R Core Team (2012) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. Available: http://www.R-project.org/ and http://www.R-project.org/.
34. Strain MC, Lada SM, Luong T, Rought SE, Gianella S, et al. (2013) Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 8: e55943.
35. Reiner AP, Lange EM, Jenny NS, Chaves PHM, Ellis J, et al. (2013) Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arterioscler Thromb Vasc Biol 33: 158-164.
36. Roe B, Coughlan S, Hassan J, Grogan A, Farrell G, et al. (2007) Elevated serum levels of interferon-gamma -inducible protein-10 in patients coinfected with hepatitis C virus and HIV. J Infect Dis 196: 1053-1057.
37. Martínez E, D'Albuquerque PM, Llibre JM, Gutierrez F, Podzamczer D, et al. (2012) Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 26: 2315-2326.
38. Wu X, Sun L, Zha W, Studer E, Gurley E, et al. (2010) HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology 138: 197-209.
39. Reingold J, Wanke C, Kotler D, Lewis C, Tracy R, et al. (2008) Association of HIV infection and HIV/ HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 48: 142-148.
40. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, et al. (2014) Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 111: 2307-2312.
41. Letendre SL, Capparelli EV, Ellis RJ, McCutchan JA (2000) Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. Antimicrob Agents Chemother 44: 2173-2175.
42. Funderburg NT, Mayne E, Sieg SF, Asaad R, Jiang W, et al. (2010) Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 115: 161-167.
43. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, et al. (2014) Soluble markers of inflammation and coagulation, but not T-cell activation, are predictors of non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 210: 1248-1259.